Literature DB >> 15624072

Challenges to evidence-based medicine: a comparison of patients and treatments in randomized controlled trials with patients and treatments in a practice research network.

Deborah A Zarin1, Julia L Young, Joyce C West.   

Abstract

BACKGROUND: The practice of evidence-based medicine depends on the availability of clinically relevant research, yet questions have been raised about the generalizability of findings from randomized controlled trials (RCTs).
OBJECTIVES: The aim of this study was to quantify differences between RCT patients and treatments and those in day-to-day clinical practice. RESEARCH
DESIGN: Data from published reports of two key RCTs underlying recent treatment advances in psychiatry were compared with data on routine psychiatric practice collected through a Practice Research Network (PRN).
SETTING: Hospital inpatient units (RCT) and the full range of psychiatric practice settings in the United States (PRN).
SUBJECTS: Adults with bipolar I disorder and adults with schizophrenia. MEASURES: Demographic (age, gender, race), clinical (principal diagnoses, comorbid conditions, psychosocial functioning, and histories of hospitalization), and treatment (medication name and dosage) characteristics.
RESULTS: PRN patients had more comorbid conditions and were more likely to be white, female, and older than RCT patients. In all, 38% of PRN patients with schizophrenia and 55% of PRN patients with bipolar I disorder would have been ineligible for the corresponding RCT. Most PRN patients receiving an RCT study medication were also receiving other medications not allowed by the RCT protocol.
CONCLUSIONS: Findings support the assertion that RCT patients and treatments are not typical of those in clinical practice, and most patients in clinical practice are receiving treatments that do not have direct empirical support. Research is needed to determine the extent to which RCT findings should be used to guide routine clinical decisions.

Entities:  

Mesh:

Year:  2005        PMID: 15624072     DOI: 10.1007/s00127-005-0838-9

Source DB:  PubMed          Journal:  Soc Psychiatry Psychiatr Epidemiol        ISSN: 0933-7954            Impact factor:   4.328


  48 in total

Review 1.  Evidence-based practice guidelines.

Authors:  D A Zarin; L Seigle; H A Pincus; J S McIntyre
Journal:  Psychopharmacol Bull       Date:  1997

2.  Generalizability of clinical studies conducted at tertiary care medical centers: a population-based analysis.

Authors:  P M Layde; S K Broste; N Desbiens; M Follen; J Lynn; D Reding; H Vidaillet
Journal:  J Clin Epidemiol       Date:  1996-08       Impact factor: 6.437

3.  Generalisability of results from randomised drug trials. A trial on antimanic treatment.

Authors:  R W Licht; G Gouliaev; P Vestergaard; M Frydenberg
Journal:  Br J Psychiatry       Date:  1997-03       Impact factor: 9.319

4.  Coping with an embarrassment of riches. How stroke centers may participate in multiple, concurrent clinical stroke trials.

Authors:  J L Saver
Journal:  Stroke       Date:  1995-07       Impact factor: 7.914

5.  Patients' willingness to enter clinical trials: measuring the association with perceived benefit and preference for decision participation.

Authors:  H A Llewellyn-Thomas; M J McGreal; E C Thiel; S Fine; C Erlichman
Journal:  Soc Sci Med       Date:  1991       Impact factor: 4.634

Review 6.  Breast cancer chemoprevention. Tamoxifen: current issues and future prospective.

Authors:  R T Chlebowski; J Butler; A Nelson; L Lillington
Journal:  Cancer       Date:  1993-08-01       Impact factor: 6.860

7.  The recruitment process for a multicenter study on the long-term prophylactic treatment of affective disorders.

Authors:  W Greil; W Ludwig-Mayerhofer; B Steller; A Czernik; H Giedke; B Müller-Oerlinghausen; M Osterheider; G A Rudolf; H Sauer; J Tegeler
Journal:  J Affect Disord       Date:  1993-08       Impact factor: 4.839

8.  Holding GUSTO up to the light. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.

Authors:  K L Lee; R M Califf; J Simes; F Van de Werf; E J Topol
Journal:  Ann Intern Med       Date:  1994-05-15       Impact factor: 25.391

9.  A comparison of demographic variables, symptom profiles, and measurements of functioning in symptomatic volunteers and an outpatient clinical population.

Authors:  M H Rapaport; T Frevert; S Babior; S Zisook; L L Judd
Journal:  Psychopharmacol Bull       Date:  1995

10.  Do volunteer subjects bias clinical trials?

Authors:  G Amori; R H Lenox
Journal:  J Clin Psychopharmacol       Date:  1989-10       Impact factor: 3.153

View more
  19 in total

1.  SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials.

Authors:  An-Wen Chan; Jennifer M Tetzlaff; Peter C Gøtzsche; Douglas G Altman; Howard Mann; Jesse A Berlin; Kay Dickersin; Asbjørn Hróbjartsson; Kenneth F Schulz; Wendy R Parulekar; Karmela Krleza-Jeric; Andreas Laupacis; David Moher
Journal:  BMJ       Date:  2013-01-08

Review 2.  Postmarketing safety surveillance : where does signal detection using electronic healthcare records fit into the big picture?

Authors:  Preciosa M Coloma; Gianluca Trifirò; Vaishali Patadia; Miriam Sturkenboom
Journal:  Drug Saf       Date:  2013-03       Impact factor: 5.606

3.  Healthcare Funding Decisions and Real-World Benefits: Reducing Bias by Matching Untreated Patients.

Authors:  Peter Ghijben; Dennis Petrie; Silva Zavarsek; Gang Chen; Emily Lancsar
Journal:  Pharmacoeconomics       Date:  2021-04-09       Impact factor: 4.981

4.  Revisiting practice-based research networks as a platform for mental health services research.

Authors:  J Curtis McMillen; Shannon L Lenze; Kristin M Hawley; Victoria A Osborne
Journal:  Adm Policy Ment Health       Date:  2009-04-28

5.  Is the volume-outcome relationship sustained in psychiatric care?

Authors:  Hsin-Chien Lee; Herng-Ching Lin
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2007-06-27       Impact factor: 4.328

Review 6.  Pharmacovigilance: methods, recent developments and future perspectives.

Authors:  L Härmark; A C van Grootheest
Journal:  Eur J Clin Pharmacol       Date:  2008-06-04       Impact factor: 2.953

Review 7.  Drug treatments for schizophrenia: pragmatism in trial design shows lack of progress in drug design.

Authors:  F Cheng; P B Jones
Journal:  Epidemiol Psychiatr Sci       Date:  2013-02-06       Impact factor: 6.892

Review 8.  Reassessing the evidence hierarchy in asthma: evaluating comparative effectiveness.

Authors:  David Price; Alison Chisholm; Thys van der Molen; Nicolas Roche; Elizabeth V Hillyer; Jean Bousquet
Journal:  Curr Allergy Asthma Rep       Date:  2011-12       Impact factor: 4.806

9.  Five-year review of an international clinical research-training program.

Authors:  Claudia Kimie Suemoto; Sherine Ismail; Paulo César Rodrigues Pinto Corrêa; Faiza Khawaja; Teodoro Jerves; Laura Pesantez; Ana Claudia Camargo Gonçalves Germani; Fabio Zaina; Augusto Cesar Soares Dos Santos; Ricardo Jorge de Oliveira Ferreira; Priyamvada Singh; Judy Vicente Paulo; Suely Reiko Matsubayashi; Liliane Pinto Vidor; Guilherme Andretta; Rita Tomás; Ben Mw Illigens; Felipe Fregni
Journal:  Adv Med Educ Pract       Date:  2015-04-01

10.  Improving the reporting of pragmatic trials: an extension of the CONSORT statement.

Authors:  Merrick Zwarenstein; Shaun Treweek; Joel J Gagnier; Douglas G Altman; Sean Tunis; Brian Haynes; Andrew D Oxman; David Moher
Journal:  BMJ       Date:  2008-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.